Journal
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Volume 78, Issue 10, Pages 1697-1701Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00228-022-03370-7
Keywords
SARS-CoV-2; Seizure; Anticonvulsants; Nirmatrelvir; Ritonavir; Dosing; Drug interaction
Categories
Ask authors/readers for more resources
Management and dose adjustment are important considerations for clinicians when co-exposure to nirmatrelvir/ritonavir occurs in patients taking antiepileptic drugs. This study identified specific antiepileptic drugs that require dose adjustment due to drug-drug interactions between nirmatrelvir/ritonavir and the antiepileptic drugs. The findings recommend dose adjustment of nirmatrelvir/ritonavir instead of certain antiepileptic drugs to avoid potential threats in epilepsy patients.
Management and dose adjustment are a major concern for clinicians in the absence of specific clinical outcome data for patients on antiepileptic drugs (AEDs), in the event of short-term (5 days) nirmatrelvir/ritonavir co-exposure. Therefore, in this report, we identified drugs that require dose adjustment because of drug-drug interactions (DDIs) between nirmatrelvir/ ritonavir and AEDs. We hereby used four databases (Micromedex Drug Interaction, Liverpool Drug Interaction Group for COVID-19 Therapies, Medscape Drug Interaction Checker, and Lexicomp Drug Interactions) and DDI-Predictor. In the light of applying the DDI-Predictor, for carbamazepine, clobazam, oxcarbazepine, eslicarbazepine, phenytoin, phenobarbital, pentobarbital, rufinamide, and valproate as CYP3A4 inducers, we recommend that a dose adjustment of short-term nirmatrelvir/ritonavir as a substrate (victim) drug would be more appropriate instead of these AEDs to avoid impending DDI-related threats in patients with epilepsy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available